AMRN: שווי שוק להכנסות Amarin Corp
Geopolitical instability and patent conflicts pose threats to the exclusivity of Amarin Corporation plc (AMRN) cardiovascular drugs. On GURU.Markets, the P/S ratio demonstrates the market's view on the asset's resilience, where 1.40 serves as the base value of the parameter. Margin compression risks resulting from the loss of intellectual property protection are mitigated by the diversification of contract manufacturing in Asia and Europe, which ensures the stable production of substances.
פילוחי מדדים ואנליטיקה של חברת Amarin Corporation (AMRN)
The P/S ratio reflects the market value of the business relative to its annual revenue, allowing for an assessment of the premium investors are paying for every dollar of sales. By analyzing the normalized P/S of Amarin Corporation plc (AMRN), one can identify points of extreme undervaluation, which is critically important for Amarin Corporation plc (AMRN) during a period of technological stagnation and the loss of patent protection for its primary drug, Vascepa.
